Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 2Neoplasms 2Fallopian Tube Neoplasms 2Uterine Neoplasms 1Triple-negative Metastatic Breast Cancer 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Laryngeal Neoplasms 1Glioblastoma 1Colorectal Neoplasms 1Chromosome 5q Deletion Syndrome 1Carcinoma, Ovarian Epithelial 1Carcinoma 1

Interventions

Paclitaxel 10Surveys and Questionnaires 6Cisplatin 6Carboplatin 5pembrolizumab 4Brachytherapy 4Hyperthermic Intraperitoneal Chemotherapy 3Gemcitabine 3Doxorubicin 3Docetaxel 3olaparib 2niraparib 2durvalumab 2Topotecan 2Taxes 2Standard of Care 2Sentinel Lymph Node Biopsy 2Saline Solution 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Music Therapy 2Mitomycin 2Letrozole 2Imagery, Psychotherapy 2Hysterectomy 2Exercise 2Everolimus 2Blood Specimen Collection 2ulipristal acetate 1temsirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Uterine Neoplasms × adavosertib × Clear all
NCT03668340 2026-01-12

AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
49 enrolled
Gynecologic

Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡